EAM
Exome Asset Management Portfolio holdings
AUM
$110M
1-Year Return
24.83%
This Quarter Return
-6.4%
1 Year Return
+24.83%
3 Year Return
–
5 Year Return
–
10 Year Return
–
AUM
$112M
AUM Growth
-$21.3M
(-16%)
Cap. Flow
-$14.9M
Cap. Flow
% of AUM
-13.34%
Top 10 Holdings %
Top 10 Hldgs %
39.5%
Holding
78
New
15
Increased
14
Reduced
14
Closed
24
Top Buys
| 1 |
AstraZeneca
AZN
|
$4.73M |
| 2 |
Cogent Biosciences
COGT
|
$3.72M |
| 3 |
Viridian Therapeutics
VRDN
|
$2.93M |
| 4 |
Regenxbio
RGNX
|
$2.9M |
| 5 |
Dyne Therapeutics
DYN
|
$2.7M |
Top Sells
| 1 |
Humana
HUM
|
$4.58M |
| 2 |
Relay Therapeutics
RLAY
|
$4.46M |
| 3 |
Apellis Pharmaceuticals
APLS
|
$3.81M |
| 4 |
Bristol-Myers Squibb
BMY
|
$3.69M |
| 5 |
Boston Scientific
BSX
|
$3.62M |
Sector Composition
| 1 | Healthcare | 98.64% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
GE HealthCare
GEHC
$33.8B
| $2.05M | 1.82% |
+25,400
| New | +$2.05M |
|
27
Fulcrum Therapeutics
FULC
$372M
| $1.98M | 1.76% |
689,137
+405,538
| +143% | +$1.17M |
|
28
Structure Therapeutics
GPCR
$1.14B
| $1.78M | 1.58% |
102,944
-49,021
| -32% | -$849K |
|
29
Immunome
IMNM
$853M
| $1.78M | 1.58% |
+263,841
| New | +$1.78M |
|
|
ONC
30
BeOne Medicines Ltd. American Depositary Shares
ONC
$35.1B
| $1.77M | 1.57% |
6,500
-3,500
| -35% | -$953K |
|
31
Crinetics Pharmaceuticals
CRNX
$3.23B
| $1.72M | 1.53% |
+51,295
| New | +$1.72M |
|
32
Edgewise Therapeutics
EWTX
$1.54B
| $1.57M | 1.4% |
71,438
-10,035
| -12% | -$221K |
|
33
Dr. Reddy's Laboratories
RDY
$11.8B
| $1.55M | 1.38% |
117,500
| – | – |
|
34
Corbus Pharmaceuticals
CRBP
$123M
| $1.54M | 1.37% |
+289,690
| New | +$1.54M |
|
35
Nektar Therapeutics
NKTR
$684M
| $1.52M | 1.35% |
148,830
+107,618
| +261% | +$1.1M |
|
36
Arvinas
ARVN
$559M
| $1.37M | 1.22% |
195,295
-23,405
| -11% | -$164K |
|
37
Gossamer Bio
GOSS
$571M
| $1.21M | 1.07% |
1,097,999
| – | – |
|
38
Trevi Therapeutics
TRVI
$880M
| $1.03M | 0.92% |
+163,738
| New | +$1.03M |
|
|
MBX
39
MBX Biosciences, Inc. Common Stock
MBX
$434M
| $982K | 0.87% |
+133,113
| New | +$982K |
|
40
Biohaven
BHVN
$1.7B
| $959K | 0.85% |
39,900
+11,741
| +42% | +$282K |
|
41
Alvotech
ALVO
$2.51B
| $871K | 0.77% |
90,100
| – | – |
|
42
VYNE Therapeutics
VYNE
$7.91M
| $731K | 0.65% |
462,801
+109,367
| +31% | +$173K |
|
43
Establishment Labs
ESTA
$1.12B
| $535K | 0.48% |
13,100
| – | – |
|
44
BioCryst Pharmaceuticals
BCRX
$1.74B
| $455K | 0.4% |
+60,600
| New | +$455K |
|
45
Eledon Pharmaceuticals
ELDN
$156M
| $387K | 0.34% |
114,145
-142,228
| -55% | -$482K |
|
46
Akebia Therapeutics
AKBA
$801M
| $363K | 0.32% |
189,087
-16,869
| -8% | -$32.4K |
|
47
Nuvation Bio
NUVB
$1.17B
| $170K | 0.15% |
+96,311
| New | +$170K |
|
48
Aprea Therapeutics
APRE
$8.74M
| $59.1K | 0.05% |
28,972
-98,988
| -77% | -$202K |
|
|
SLRN
49
DELISTED
ACELYRIN
SLRN
| – | – |
-234,435
| Closed | -$736K |
|
50
Summit Therapeutics
SMMT
$17.7B
| – | – |
-130,412
| Closed | -$2.33M |
|